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Abstract An 83-year-old female, who had a history of anterior myocardial infarc-
tion, was treated for Alzheimer’s disease with donepezil. She suffered from repeated
diarrhea and vomiting, and experienced syncope. She was admitted to our hos-
pital and was diagnosed with acute colitis and syncope. On admission, her heart
rate was 54 beats/min with regular rhythm. Laboratory data showed a low plasma
potassium level. Electrocardiogram (ECG) showed poor R progression, ST elevation,
negative T in precordial leads, and marked QT prolongation. Transthoracic echocar-
diogram showed the enlargement of the left atrium and aneurysmal area at the
apex. Torsades de Pointes (TdP) with syncope and convulsion were conﬁrmed on
ECG monitoring twice after admission. We treated her with potassium chloride and
started magnesium sulfate and lidocaine, and then added isoprenaline injection.
After these treatments, her heart rate increased and we did not detect TdP again.
With the aging population in Japan, prescriptions for donepezil are increasing. We
have to be vigilant for syncope in patients taking donepezil, which is possibly related
to QT prolongation and TdP.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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1. Introduction
Donepezil is a cholinesterase inhibitor prescribed
for patients with Alzheimer’s disease. With the
aging society in Japan, the prescriptions for
donepezil are increasing. In addition, at present,
there are no alternative oral drugs to delay the
progression of Alzheimer’s disease in Japan. We
experienced a case of Torsades de Pointes (TdP)
with QT prolongation in a patient suffering from
Alzheimer’s disease and taking donepezil.
2. Case report
An 83-year-old female was treated for Alzheimer’s
disease with donepezil (Aricept®, Eisai Co. Ltd.,
Japan) 5mg/day for at least 2 years by her home
physician. She also had hypertension, which had
been treated with bisoprolol 5mg/day, diabetes
mellitus, paroxysmal atrial ﬁbrillation, and a his-
tory of anterior myocardial infarction (10 years
previously). She suffered from repeated diarrhea
and vomiting from the morning, turned pale, and
ﬁnally developed syncope. Then she was brought
to our hospital by an ambulance in the evening,
admitted, and was diagnosed with acute colitis and
syncope. She had no previous history of syncope. On
admission, she was slightly obese (the height was
v
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Figure 1 Changes in electrocardiogram (precordial leads). Th
(A) Admission, (B) next day and (C) the 14th day.T. Takaya et al.
46 cm and the weight 56 kg). Her heart rate was
4 beats/min, regular rhythm, and blood pressure
as 148/63mmHg. The oxygen saturation was 96%
n room air. She had no cardiac murmur, rales, or leg
dema. Her bowel sound was sthenic, and there was
requent and much watery stool after admission.
Laboratory data showed high white blood cell
ount (11,900/L), a low plasma potassium level
3.3mEq/L), and a high plasma brain natri-
retic peptide level (318.7 pg/ml). Renal and
iver dysfunction was not conﬁrmed (aspartate
minotransferase 16 IU/L, alanine aminotrans-
erase 7 IU/L, blood urea nitrogen 17.9mg/dL,
reatinine 0.8mg/dL). Electrocardiogram (ECG)
emonstrated poor R progression, ST elevation in
1—3 leads, negative T in V2—5 leads, and QTc
corrected QT interval) prolongation (645msec)
Figure 1A). Chest X-ray disclosed an enlarged car-
iac silhouette (cardiothoracic ratio: 60%), but no
ung congestion. Transthoracic echocardiography
TTE) revealed aneurysmal area at the apex. The
iameter of the end-diastolic left ventricle was
2mm, that of the end-systole 27mm, and the ejec-
ion fraction of the left ventricle was 56%. The size
f the left atrium reached 47mm and signiﬁcant
alvular failure was not detected.
Ventricular premature contraction (VPC) was
requently recorded on continuous ECG monitor-
ng just after admission. We discontinued all oral
rugs and corrected hypovolemia and the abnor-
e apparent QT prolongation was detected on admission.
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aFigure 2 Clinica
al balance of electrolytes by intravenous injection
ith a potassium supplement (Figure 2). Prompt
orrection of plasma potassium level was, how-
ver, very difﬁcult because of the frequent watery
tool. Five hours later, we detected Torsades de
ointes for 35 s on ECG monitoring (Figure 3A), and
tarted intravenous injection of magnesium sulfate
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igure 3 Continuous ECG monitoring detected Torsades de P
nd (B) 2nd event (TdP sustained for 15 s).rse of the case.
nd lidocaine (Figure 2). After an additional 5 h,
t midnight, we detected TdP again with transient
onvulsion and syncope (Figure 3B), and discussed
he use of a temporary external pacemaker. She,
owever, could not keep complete rest at that time,
nd we selected, therefore, the use of isoprenaline
njection (Figure 2). After this administration, her
ointes (TdP) twice. (A) 1st event (TdP sustained for 35 s)
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mean heart rate increased to 80—90 beats/min, and
the frequency of VPC decreased. We did not detect
TdP again thereafter.
On the second day, her rhythm turned to atrial
ﬁbrillation and this arrhythmia terminated with a
long pause (8.0 s) next day. We gradually decreased
isoprenaline and changed to oral preparations of
cilostazol and orciprenaline (Figure 2). We per-
formed catheter examination on the 13th day.
Coronary angiography revealed triple vessel dis-
ease. The left circumﬂex artery was occluded at
the proximal portion and was ﬁlled with good col-
lateral ﬂow from the right coronary artery. The
left anterior descending artery had diffuse calciﬁed
stenotic lesions from the mid to distal portion and
the right coronary artery also had a mild stenotic
lesion in the proximal portion. During the elec-
trophysiological study, her rhythm turned to atrial
ﬁbrillation again by electric stimulation, and we
could not evaluate the extent of conduction dis-
order completely. The corrected sinus recovering
time was 340msec and the HV interval was 39msec.
Three hours later, when the atrial ﬁbrillation spon-
taneously terminated, we only detected a short
pause on continuous ECG monitoring (2.1 s).
Discussing with the patient and her family, we
selected medical follow-up considering her age,
activities of daily living (ADL), and background.
After washout of donepezil, we did not ﬁnd wors-
ening of dementia during admission. QTc interval
in ECG gradually decreased (Figure 1C) and was
485msec (QTc) on the fourteenth day. We adjusted
her oral preparations and she was discharged in a
stable condition.
3. Discussion
Donepezil is a central non-competitive reversible
cholinesterase inhibitor and has been reported
to be effective for all stages of Alzheimer’s dis-
ease [1]. Donepezil can suppress the progression
of dementia and maintain the ability of per-
ception, cognition, global functioning, behavioral
symptoms, and ADL [2]. Because of the increasing
aging population, the prescriptions for donepezil
are increasing. In addition, at present, there is no
alternative oral preparation in Japan to delay the
progression of Alzheimer’s disease, which is known
for its high mortality rate [3].
The frequent side effects of donepezil are
appetite loss, nausea, and vomiting. In addition,
donepezil is also known to cause bradycardia,
sick sinus syndrome, or another arrhythmia by its
cholinergic effect relating to vagal tone stimula-
tion [4]. In some cases, discontinuation of donepezil
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s necessary. But, Bordier et al. [5] previously
ecommended the implantation of a permanent
acemaker for patients with bradycardia rather
han discontinuation of donepezil, because this
pproach enables us to increase the dosage of
onepezil. Almost all patients taking donepezil are
ged people, in whom heart rate decreases with
ging and the ability of handling the drug is often
isturbed, and therefore often those side effects
ave been reported. Regarding the side effects of
onepezil on cardiac rhythm, to our knowledge,
here is only one report that showed a reduction
f heart rate and the prolongation of PR interval,
ut these changes were not necessarily associated
ith bradycardia-induced syncope [6]. In our case,
e conﬁrmed a long pause just after the withdrawal
f donepezil, which indicated that she might have
otential sick sinus syndrome. This event, however,
ccurred during the washout period of donepezil,
nd we thought this bradycardia might also be
elated to donepezil. The half-life of donepezil in
lood ranges from 70 to 100 h and we did not detect
ither bradycardia or TdP after the washout of the
rug in this case.
It has been reported that about 3% of oral
reparations are capable of prolonging QT interval
7]. TdP due to acquired QT prolongation syn-
rome is related to multiple factors, such as aging,
emale, taking beta-blocker, hypo-potassium, and
aseline cardiac abnormalities such as ischemic
eart disease [8]. In this case, coronary angiogra-
hy revealed triple vessel disease and we thought
hat ischemia was likely involved in this arrhyth-
ic event. Her plasma donepezil level on admission
as 21.3 ng/ml, a slightly high level, but this
evel did not necessarily mean overdose (the aver-
ge blood concentrations of healthy volunteers
ho take donepezil for 14 days: 15—20 ng/ml).
rug-induced QT prolongation syndrome did not
ecessarily depend on the plasma drug concentra-
ions [8], and the mechanism was reported mainly
s the blocking of potassium Ikr current, altered
rafﬁcking of proteins that form the channel, or
elay of repolarization and prolongation of the con-
istent potential time of cardiac muscle. She might
ave abnormal sensitivity to donepezil or potential
T prolongation syndrome. Though Kato et al. [9]
eported that donepezil did not induce QT prolon-
ation in young volunteers, they did not evaluate
he side effects associated with long-time use or
hose in aged patients.Donepezil is prone to be prescribed to patients
ith only aging or to cases suspected of transient
ntensive care unit syndrome. In our case, donepezil
ad been prescribed since the previous admission
o another hospital, and we could not fully eval-
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ate the precise judgment on the indication of
onepezil. After the withdrawal of donepezil, her
ental state was almost stable and we could handle
er dementia without donepezil. Since donepezil
ight cause fatal side effects, more careful atten-
ion should be paid for the induction of this drug.
lthough QT prolongation associated with the use
f galantamine, another cholinesterase inhibitor
sed for Alzheimer’s disease, has been shown [4],
o detailed accounts on the association of TdP
ith the use of cholinesterase inhibitors have been
eported. Our report may serve to give a warning
gainst the easy use of a cholinesterase inhibitor
or aged patients with Alzheimer’s disease.
We experienced a case of TdP with QT prolonga-
ion in a patient suffering from Alzheimer’s disease
nd taking donepezil. If patients taking donepezil
xperience syncope complicated with bradycardia,
ypo-potassium, or ischemic heart disease, we have
o pay much care to the intermittent ECG and QTc
nterval. That event might be due to QT prolonga-
ion and TdP.eferences
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